TATA-box binding protein associated factor 9b pseudogene 1Genealiases: []
Q-omics provides the consensus-scored TAF9BP1 profile across patient tissues and cancer cell-line models. TAF9BP1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TAF9BP1 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, TAF9BP1 RNA expression shows 15,048 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, THCA, and UVM as cancer lineages where TAF9BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF9BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF9BP1 survival associations across molecular data types. TAF9BP1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF9BP1 RNA expression–survival associations across cancer types. High TAF9BP1 expression shows unfavorable associations in KICH, MESO, UCEC, LGG and UVM, but favorable associations in LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TAF9BP1 RNA expression.
This table summarizes TAF9BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TAF9BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF9BP1 shows lower tumor expression in THCA, BRCA and LIHC and higher tumor expression in HNSC. The THCA box plot shows higher TAF9BP1 RNA expression in normal versus tumor tissue (log2 FC = −0.094, t-test p = .017).
This table shows molecular features associated with TAF9BP1 in patient tissues and cancer cell lines. In patient samples, TAF9BP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
